These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23653048)

  • 81. BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.
    Paculová H; Kramara J; Šimečková Š; Fedr R; Souček K; Hylse O; Paruch K; Svoboda M; Mistrík M; Kohoutek J
    Tumour Biol; 2017 Oct; 39(10):1010428317727479. PubMed ID: 29025359
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The role of autophagic cell death and apoptosis in irinotecan-treated p53 null colon cancer cells.
    Stanislav J; Mls J; Červinka M; Rudolf E
    Anticancer Agents Med Chem; 2013 Jun; 13(5):811-20. PubMed ID: 22721392
    [TBL] [Abstract][Full Text] [Related]  

  • 83. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.
    Alagoz M; Gilbert DC; El-Khamisy S; Chalmers AJ
    Curr Med Chem; 2012; 19(23):3874-85. PubMed ID: 22788763
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.
    Basseville A; Preisser L; de Carné Trécesson S; Boisdron-Celle M; Gamelin E; Coqueret O; Morel A
    Mol Cancer; 2011 Jul; 10():80. PubMed ID: 21733184
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells.
    McPherson LA; Shen Y; Ford JM
    Cancer Lett; 2014 Feb; 343(2):217-23. PubMed ID: 24215868
    [TBL] [Abstract][Full Text] [Related]  

  • 86. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
    Coussy F; El-Botty R; Château-Joubert S; Dahmani A; Montaudon E; Leboucher S; Morisset L; Painsec P; Sourd L; Huguet L; Nemati F; Servely JL; Larcher T; Vacher S; Briaux A; Reyes C; La Rosa P; Lucotte G; Popova T; Foidart P; Sounni NE; Noel A; Decaudin D; Fuhrmann L; Salomon A; Reyal F; Mueller C; Ter Brugge P; Jonkers J; Poupon MF; Stern MH; Bièche I; Pommier Y; Marangoni E
    Sci Transl Med; 2020 Feb; 12(531):. PubMed ID: 32075943
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Design, synthesis and development of a dual inhibitor of Topoisomerase 1 and poly (ADP-ribose) polymerase 1 for efficient killing of cancer cells.
    Guha Majumdar A; Shree S; Das A; Kumar BK; Dey P; Subramanian M; Patro BS
    Eur J Med Chem; 2023 Oct; 258():115598. PubMed ID: 37406384
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Expressing
    Huang Y; Feng L; Bao Y; Zhang Y; Liang J; Mao Q; Li J; Jiang C
    Exp Biol Med (Maywood); 2022 Mar; 247(5):426-432. PubMed ID: 34787019
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.
    Abu-Sanad A; Wang Y; Hasheminasab F; Panasci J; Noë A; Rosca L; Davidson D; Amrein L; Sharif-Askari B; Aloyz R; Panasci L
    Front Pharmacol; 2015; 6():147. PubMed ID: 26257651
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Synergistic anticancer effects of curcumin and 3',4'-didemethylnobiletin in combination on colon cancer cells.
    DiMarco-Crook C; Rakariyatham K; Li Z; Du Z; Zheng J; Wu X; Xiao H
    J Food Sci; 2020 Apr; 85(4):1292-1301. PubMed ID: 32144766
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Mus81 knockdown sensitizes colon cancer cells to chemotherapeutic drugs by activating CHK1 pathway.
    Wu F; Su SC; Tan GQ; Yan L; Li TY; Zhang HL; Yu JS; Wang BL
    Clin Res Hepatol Gastroenterol; 2017 Oct; 41(5):592-601. PubMed ID: 28291626
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Targeting Topoisomerase I in the Era of Precision Medicine.
    Thomas A; Pommier Y
    Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Antimutagenicity of cinnamaldehyde and vanillin in human cells: Global gene expression and possible role of DNA damage and repair.
    King AA; Shaughnessy DT; Mure K; Leszczynska J; Ward WO; Umbach DM; Xu Z; Ducharme D; Taylor JA; Demarini DM; Klein CB
    Mutat Res; 2007 Mar; 616(1-2):60-9. PubMed ID: 17178418
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
    Rolle CE; Kanteti R; Surati M; Nandi S; Dhanasingh I; Yala S; Tretiakova M; Arif Q; Hembrough T; Brand TM; Wheeler DL; Husain AN; Vokes EE; Bharti A; Salgia R
    Mol Cancer Ther; 2014 Mar; 13(3):576-84. PubMed ID: 24327519
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cell diameter measurements obtained with a handheld cell counter could be used as a surrogate marker of G2/M arrest and apoptosis in colon cancer cell lines exposed to SN-38.
    Tahara M; Inoue T; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
    Biochem Biophys Res Commun; 2013 May; 434(4):753-9. PubMed ID: 23583407
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses.
    Miao ZH; Player A; Shankavaram U; Wang YH; Zimonjic DB; Lorenzi PL; Liao ZY; Liu H; Shimura T; Zhang HL; Meng LH; Zhang YW; Kawasaki ES; Popescu NC; Aladjem MI; Goldstein DJ; Weinstein JN; Pommier Y
    Cancer Res; 2007 Sep; 67(18):8752-61. PubMed ID: 17875716
    [TBL] [Abstract][Full Text] [Related]  

  • 97. MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy.
    Paillas S; Causse A; Marzi L; de Medina P; Poirot M; Denis V; Vezzio-Vie N; Espert L; Arzouk H; Coquelle A; Martineau P; Del Rio M; Pattingre S; Gongora C
    Autophagy; 2012 Jul; 8(7):1098-112. PubMed ID: 22647487
    [TBL] [Abstract][Full Text] [Related]  

  • 98. RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.
    Martin SE; Wu ZH; Gehlhaus K; Jones TL; Zhang YW; Guha R; Miyamoto S; Pommier Y; Caplen NJ
    Curr Cancer Drug Targets; 2011 Oct; 11(8):976-86. PubMed ID: 21834757
    [TBL] [Abstract][Full Text] [Related]  

  • 99. MutL protein homologue 1(MLH1) in colon adenocarcinomas of the dog: minireview.
    Makovický P; Caja F; Vodicková L; Makovický P; Cervinková M; Juhász A; Samasca G; Vodicka P
    Cesk Fysiol; 2016 Oct; 65(2):88-93. PubMed ID: 29489087
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Loss of Nek11 Prevents G2/M Arrest and Promotes Cell Death in HCT116 Colorectal Cancer Cells Exposed to Therapeutic DNA Damaging Agents.
    Sabir SR; Sahota NK; Jones GD; Fry AM
    PLoS One; 2015; 10(10):e0140975. PubMed ID: 26501353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.